Ellis H, Braconi C, Valle J, Bardeesy N
Am J Pathol. 2024; 195(3):437-452.
PMID: 39730074
PMC: 11841491.
DOI: 10.1016/j.ajpath.2024.11.005.
Liao C, Gonzalez-Ferrer C, Whipple S, Peterson P, Barker S, Bhandari N
Cancers (Basel). 2024; 16(22).
PMID: 39594790
PMC: 11592841.
DOI: 10.3390/cancers16223835.
Zhang Y, Zheng W, Zhou S, Gu J, Yu Q, Zhu Y
Cell Commun Signal. 2024; 22(1):460.
PMID: 39342195
PMC: 11439284.
DOI: 10.1186/s12964-024-01837-x.
Huang D, Zhang J, Zheng X, Gao M
Heliyon. 2024; 10(11):e31681.
PMID: 38841496
PMC: 11152703.
DOI: 10.1016/j.heliyon.2024.e31681.
Hackshaw A, Fajardo O, Dafni U, Gelderblom H, Garrido P, Siena S
JCO Precis Oncol. 2024; 8:e2300334.
PMID: 38271655
PMC: 10830092.
DOI: 10.1200/PO.23.00334.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui A, Kato M, Suzuki T
Nat Cancer. 2023; 4(9):1345-1361.
PMID: 37743366
PMC: 10518257.
DOI: 10.1038/s43018-023-00630-y.
Precision oncology with selective RET inhibitor selpercatinib in -rearranged cancers.
Gouda M, Subbiah V
Ther Adv Med Oncol. 2023; 15:17588359231177015.
PMID: 37360768
PMC: 10288430.
DOI: 10.1177/17588359231177015.
Hereditary cancer syndromes.
Imyanitov E, Kuligina E, Sokolenko A, Suspitsin E, Yanus G, Iyevleva A
World J Clin Oncol. 2023; 14(2):40-68.
PMID: 36908677
PMC: 9993141.
DOI: 10.5306/wjco.v14.i2.40.
Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.
Yokota T
Case Rep Oncol. 2023; 15(3):833-840.
PMID: 36825106
PMC: 9941774.
DOI: 10.1159/000526030.
Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.
Yuan J, Guo Y
Cancers (Basel). 2023; 15(1).
PMID: 36612173
PMC: 9818071.
DOI: 10.3390/cancers15010179.
Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
Keck M, Sill M, Wittmann A, Joshi P, Stichel D, Beck P
Acta Neuropathol. 2022; 145(1):49-69.
PMID: 36437415
PMC: 9807491.
DOI: 10.1007/s00401-022-02516-2.
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Kucharczyk T, Krawczyk P, Kowalski D, Pluzanski A, Kubiatowski T, Kalinka E
Cancers (Basel). 2022; 14(21).
PMID: 36358717
PMC: 9657474.
DOI: 10.3390/cancers14215298.
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Kalchiem-Dekel O, Falcon C, Bestvina C, Liu D, Kaplanis L, Wilhelm C
J Thorac Oncol. 2022; 17(9):1130-1136.
PMID: 35788405
PMC: 9427698.
DOI: 10.1016/j.jtho.2022.06.008.
Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.
Shehata M, Contreras J, Martin-Hurtado A, Froux A, Mohamed H, El-Sherif A
J Adv Res. 2022; 45:87-100.
PMID: 35595215
PMC: 10006619.
DOI: 10.1016/j.jare.2022.05.004.
A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer.
Liu W, Gajendran B, Sample K, Wang C, Hu A, Chen B
Cancer Gene Ther. 2022; 29(11):1590-1599.
PMID: 35477769
DOI: 10.1038/s41417-022-00471-4.
The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
Wu G, Guo L, Gu Y, Huang T, Liu M, Zou X
J Cancer Res Clin Oncol. 2022; 149(3):1019-1028.
PMID: 35220468
PMC: 9984339.
DOI: 10.1007/s00432-022-03959-6.
Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
Pavanelli A, Mangone F, Yoganathan P, Bessa S, Nonogaki S, de Toledo Osorio C
Breast Cancer Res Treat. 2022; 192(1):43-52.
PMID: 35031902
DOI: 10.1007/s10549-021-06452-9.
Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M, Wang W, Zhang J, Li B, Lv D, Wang D
Cancer Sci. 2021; 113(1):308-318.
PMID: 34710947
PMC: 8748217.
DOI: 10.1111/cas.15181.
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Wirth L, Robinson B, Boni V, Tan D, McCoach C, Massarelli E
Oncologist. 2021; 27(1):13-21.
PMID: 34516023
PMC: 9714586.
DOI: 10.1002/onco.13977.
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee Y, Lee H, Im S, Song Y, Oh D, Kang H
J Clin Invest. 2021; 131(18).
PMID: 34237031
PMC: 8439610.
DOI: 10.1172/JCI144847.
